Alimera Sciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of ophthalmic pharmaceuticals. It develops pharmaceuticals for diseases affecting the back of the eye or retina. The company's product candidates include Iluvien, an intravitreal insert that provides a sustained therapeutic effect for up to 36 months in the treatment of diabetic macular edema; or DME, a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness, as well as other ophthalmic diseases, such as the wet form of age-related macular degeneration (AMD), the dry form of AMD, and retinal vein occlusion. It also conducts testing on two classes of Nicotinamide Adenine Dinucleotide Phosphate oxidase inhibitors. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.